Adenoviral (Full-Length) Apo2L/TRAIL Gene Transfer is an Ineffective Treatment Strategy for Malignant Glioma

@article{Naumann2003AdenoviralA,
  title={Adenoviral (Full-Length) Apo2L/TRAIL Gene Transfer is an Ineffective Treatment Strategy for Malignant Glioma},
  author={Ulrike Naumann and Robert Waltereit and J{\"o}rg Bernhard Schulz and Michael Weller},
  journal={Journal of Neuro-Oncology},
  year={2003},
  volume={61},
  pages={7-15}
}
Death ligand-mediated apoptosis is a promising strategy of gene therapy for human malignant glioma. We here report that the infection of human malignant glioma cell lines with an adenoviral vector encoding full length human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Ad-Apo2L/TRAIL) results in strong Apo2L/TRAIL transgene expression and the release of full-length Apo2L/TRAIL into the cell culture medium. However, Ad-Apo2L/TRAIL is a poor inducer of cell death, even in… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Quantification of cytotoxicity by cell volume and cell proliferation

  • P Winkelmeir, B Glaubner, T Lindl
  • ALTA 21:
  • 1993
Highly Influential
4 Excerpts

Broghammer EL: Suppression of tumor growth following intralesional therapy with TRAIl recombinant adenovirus

  • TS Griffith
  • Mol Ther
  • 2001
2 Excerpts

Similar Papers

Loading similar papers…